This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Merck & Co., Inc.

Drug Names(s): MK-8742/MK-5172

Description: Merck is developing a fixed dose combination of MK-8742 (elbasvir), a HCV nonstructural protein NS5a inhibitor, and MK-5172 (grazoprevir), a second generation HCV NS3/4A protease inhibitor.

Zepatier News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug